Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Nicole Egli"'
Autor:
Patrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, Laetitia Petersen, Nicole Egli, Simone Popp, Catherine Regnier, Kirsten Richter, Andreas Katopodis, Christoph Huber
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivity toward effector over regulatory T cells and reducing dose-limiting toxicities. Here we describe ANV419, an IL-2/anti-IL2 an
Externí odkaz:
https://doaj.org/article/c58320a3176c45a68cbb1b5dbf7c8122
Autor:
Christoph Huber, Christian Stocker, Kirsten Richter, Patrizia Murer, Ulisse Salazar, Nicole Egli, Laetitia Petersen, Pia Neubert, Alexander Rau, Andreas Katopodis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/1c1b7dc490854a6cb59a691478325535
Autor:
Ulrike Strittmatter-Keller, Caroline Walter, Celine Rauld, Nicole Egli, Camille Regairaz, Sabine Rabe, Gerhard Zenke, José Carballido, Tamás Schweighoffer
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0208187 (2018)
Differentiation of B cells is a stringently controlled multi-step process, which is still incompletely understood. Here we identify and characterize a rare population of human B cells, which surprisingly carry CD8AB on their surface. Existence of suc
Externí odkaz:
https://doaj.org/article/c4f65b7f95b146929cc1fbe05c79a8ce
Publikováno v:
Campbell Systematic Reviews, Vol 5, Iss 1, Pp 1-40 (2009)
Drug abusers are generally more involved in crime, in particular property crime, than people who are not drug abusers. Substitution programs have been developed in order to improve drug users' quality of life and to decrease their criminal involvemen
Externí odkaz:
https://doaj.org/article/b3d38b88e47e47ddbe4477ce75c48749
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0142741 (2015)
Toll-like receptors (TLRs) are important sensors of the innate immune system that recognize conserved structural motifs and activate cells via a downstream signaling cascade. The CD180/MD1 molecular complex is an unusual member of the TLR family, sin
Externí odkaz:
https://doaj.org/article/52fd7410c06e4ddba8312f9c98f35ea8
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Patrizia Murer, Ulisse Salazar, Nicole Egli, Laetitia Petersen, Pia Neubert, Kirsten Richter, Christian Stocker, Alexander Rau, Andreas Katopodis, Christoph Huber
Publikováno v:
Cancer Research. 83:4127-4127
Non-alpha IL-2-based therapeutic modalities with preferential signaling through the IL-2 beta(CD122)/gamma(CD132) receptor are in clinical development and have the potential to substantially increase the therapeutic index of recombinant IL-2 (aldesle
Publikováno v:
Science & Justice. 59:1-8
This paper explores procedural mechanisms to resolve differing conclusions when two experts have initially worked independently. These experts can be two human examiners or one of them may be a computer-based model. The resolving process is presented
Autor:
Elena Garralda, Alonso Guzman, Juanita Lopez, Vicky Sanchez-Perez, Heinz Läubli, Emiliano Calvo, Christoph Huber, Nicole Egli, Aswathy Nair, Julie Mouton, Kirsten Richter, Carlo Lanza, Sangeeta Jethwa, Silvio Costanzo, Christoph Bucher
Publikováno v:
Cancer Research. 82:CT140-CT140
Developing a safe and effective non-alpha IL-2R agonist to enhance the numbers and activation status of immune effector cells for the treatment of cancer has remained an elusive goal since the initial approval of Interleukin-2 (IL-2). ANV419 comprise
Autor:
Heinz Läubli, Guzman Alonso, Juanita Suzanne Lopez, Emiliano Calvo, Vicky Sanchez Perez, Daniela Di Blasi, Aswathy Nair, Kirsten Richter, Christoph Huber, Nicole Egli, Julie Mouton, Silvio Costanzo, Andreas Katopodis, Sangeeta Jethwa Schnetzler, Christoph Marcus Bucher, Elena Garralda
Publikováno v:
Journal of Clinical Oncology. 40:e21552-e21552
e21552 Background: IL-2R agonists that are well tolerated and can selectively enhance immune activation may improve outcomes of patients with cancer. ANV419 is a potent and highly selective IL-2Rβγ binding agonist, consisting of an antibody specifi